Newer anticoagulants in cardiovascular disease: A systematic review of the literature

Cardiology in Review

Volumn 20, Issue 5, 2012, Pages 209-221

  Maan, Abhishek ^a   Padmanabhan, Ram ^a   Shaikh, Amir Y ^a   Mansour, Moussa ^b   Ruskin, Jeremy N ^b   Heist, E Kevin ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

direct thrombin inhibitor; factor Xa inhibitor; oral anticoagulants; vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ATECEGATRAN METOXIL; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; DALTEPARIN; DAREXABAN; DIGOXIN; EDOXABAN; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; LETAXABAN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OTAMIXABAN; PROTHROMBIN A; PROTON PUMP INHIBITOR; RIFAMPICIN; RIVAROXABAN; TECARFARIN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ACUTE LIVER FAILURE; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LUNG EMBOLISM; NONHUMAN; PHARMACODYNAMICS; PROSTHETIC VALVE THROMBOSIS; REVIEW; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; DRUG DESIGN; DRUG DISCOVERY; FACTOR XA; HEART VALVE PROLAPSE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VENOUS THROMBOSIS;

EID: 84864867307     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3182503e2d     Document Type: Review

References (127)

1. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18 349-355.
2. Wallentin L, Yusuf S, Ezekowitz MD, et al. RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation an analysis of the RE-LY trial. Lancet. 2010;376 975-983.
3. Rose AJ, Hylek EM, Ozonoff A, et al. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4 22-29.
4. Patel MR, Mahaffey KW, Garg J, et al. ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365 883-891.
5. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation a meta-analysis. Ann Intern Med. 1999;131 492-501. (Pubitemid 29482392)
6. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation an individual patient meta-analysis. JAMA. 2002;288 2441-2448. (Pubitemid 35340540)
7. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37 1070-1074.
8. Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants a basis for dose individualization. Clin Pharmacokinet. 2008;47 565-594.
9. Pérez-Andreu V, Roldán V, Antón AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113 4977-4979.
10. Klein TE, Altman RB, Eriksson N, et al. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360 753-764.
11. Ford GA, Choy AM, Deedwania P, et al. SPORTIF III and V Investigators. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation experience from the SPORTIF III and V Trials. Stroke. 2007;38 2965-2971. (Pubitemid 350035691)
12. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III) randomised controlled trial. Lancet. 2003;362 1691-1698. (Pubitemid 37468318)
13. Fiessinger JN, Huisman MV, Davidson BL, et al. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis a randomized trial. JAMA. 2005;293 681-689. (Pubitemid 40216038)
14. Agnelli G, Eriksson BI, Cohen AT, et al. EXTEND Study Group. Safety assessment of new antithrombotic agents lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123 488-497.
15. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005;28 351-370. (Pubitemid 40545769)
16. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98 155-162. (Pubitemid 47078782)
17. van Ryn J, Hauel N, Waldmann L, et al. Dabigatran inhibits both clot-bound and fluid-phase thrombin in vitro comparison to heparin and hirudin. Arterioscler Thromb Vasc Biol. 2008;28 e136-e137.
18. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47 285-295. (Pubitemid 351508116)
19. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36 386-399. (Pubitemid 351185753)
20. Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48 1411-1419.
21. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64 292-303. (Pubitemid 47283865)
22. Eisert WG, Hauel N, Stangier J, et al. Dabigatran an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30 1885-1889.
23. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49 259-268.
24. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361 1139-1151.
25. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation an analysis of patients undergoing cardioversion. Circulation. 2011;123 131-136.
26. Wann LS, Curtis AB, Ellenbogen KA, et al. American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran) a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation. 2011;123 1144-1150.
27. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361 2342-2352.
28. Eriksson BI, Dahl OE, Huo MH, et al. RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105 721-729.
29. Eriksson BI, Dahl OE, Rosencher N, et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement the RE-MODEL randomized trial. J Thromb Haemost. 2007;5 2178-2185. (Pubitemid 47617868)
30. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009;101 77-85.
31. Oldgren J, Budaj A, Granger CB, et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy a randomized, double-blind, phase II trial. Eur Heart J. 2011;32 2781-2789.
32. McKellar SH, Abel S, Camp CL, et al. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141 1410-1416.
33. Maegdefessel L, Linde T, Krapiec F, et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res. 2010;126 e196-e200.
34. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3 514-521. (Pubitemid 41632877)
35. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1 1504-1514.
36. Ansell J. Factor Xa or thrombin is factor Xa a better target? J Thromb Haemost. 2007;5(suppl 1) 60-64.
37. Furugohri T, Shiozaki Y, Muramatsu S, et al. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur J Pharmacol. 2005;514 35-42. (Pubitemid 40692761)
38. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61 873-880. (Pubitemid 41803696)
39. Weinz C, Buetehorn U, Daehler HP, et al. Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs. Xenobiotica. 2005;35 891-910. (Pubitemid 41759174)
40. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol. 2006;46 981-990. (Pubitemid 44215062)
41. Kubitza D, Becka M, Zuehlsdorf M, et al. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol. 2006;46 702.
42. Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63 469-476. (Pubitemid 46426627)
43. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46 549-558.
44. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45 555-563. (Pubitemid 40562946)
45. Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 2009;7 1313-1320.
46. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100 453-461.
47. Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358 2765-2775. (Pubitemid 351930851)
48. Kakkar AK, Brenner B, Dahl OE, et al. RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty a double-blind, randomised controlled trial. Lancet. 2008;372 31-39.
49. Lassen MR, Ageno W, Borris LC, et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358 2776-2786. (Pubitemid 351930852)
50. Turpie AG, Lassen MR, Davidson BL, et al. RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4) a randomised trial. Lancet. 2009;373 1673-1680.
51. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363 2499-2510.
52. Buller HR. Once-daily oral rivaroxaban versus placebo in long term prevention of recurrent symptomatic venous thromboembolism, the EINSTEIN extension study. ASH Annual Meeting 2009. Blood. 2009;114 LBA-Abstract 2.
53. Mega JL, Braunwald E, Mohanavelu S, et al. ATLAS ACS-TIMI 46 Study Group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46) a randomised, double-blind, phase II trial. Lancet. 2009;374 29-38.
54. Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366 9-19.
55. Roe MT, Ohman EM. A new era in secondary prevention after acute coronary syndrome. N Engl J Med. 2012;366 85-87.
56. Kaeberich A, Reindl I, Raaz U, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves results of an in vitro study. J Thromb Thrombolysis. 2011;32 417-425.
57. Luettgen JM, Wang Z, Seiffert DA, et al. Inhibition of measured thrombin generation in human plasma by apixaban a predictive mathematical model based on experimentally determined rate constants. J Thromb Haemost. 2007;5(suppl 2) 633.
58. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6 820-829. (Pubitemid 351524543)
59. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37 74-81.
60. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost. 2008;6 1736-1741.
61. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006;15 843-855. (Pubitemid 44177839)
62. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50 5339-5356. (Pubitemid 350057846)
63. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38 448-458.
64. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364 806-817.
65. Lopes RD, Alexander JH, Al-Khatib SM, et al. ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial design and rationale. Am Heart J. 2010;159 331-339.
66. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365 981-992.
67. Lassen MR, Gallus AS, Pineo GF et al. Randomized double blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement the ADVANCE-1 trial. ASH Annual Meeting 2008. Blood. 2008;112 abstract 31.
68. Lassen MR, Raskob GE, Gallus A, et al. ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2) a randomised double-blind trial. Lancet. 2010;375 807-815.
69. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119 2877-2885.
70. Alexander JH, Lopes RD, James S, et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365 699-708.
71. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007;98 883-888. (Pubitemid 47555083)
72. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6 1542-1549.
73. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50 743-753.
74. Ridout G, de la Motte S, Niemczyk S, et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model (abstract). J Clin Pharmacol. 2009;49 1124.
75. Yasaka M, Inoue H, Yamaguchi T, et al. Randomized, parallel group, multicenter phase II study evaluating safety of DU-176b in Japanese subjects with non-valvular atrial fibrillation. (NVAF) (abstract). J Thromb Haemost. 2009;7 376.
76. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104 633-641.
77. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160 635-641.
78. Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010;104 642-649.
79. Fuji T, Fujita S, Tachibana S, et al. Randomized, double blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty. ASH Annual Meeting 2008. Blood. 2008;112 abstract 34.
80. Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5- methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009;19 2179-2185.
81. Ezekowitz M. Explore Xa study (NCT 00742859) randomized clinical trial of three doses of long acting direct factor Xa inhibitor betrixaban in patients with atrial fibrillation. Presented at American College of Cardiology's 59th Annual Scientific Session, March 15, 2010.
82. Turpie AG, Bauer KA, Davidson BL, et al. EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101 68-76.
83. Lip GY, Rasmussen LH, Olsson SB, et al. Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009;30 2897-2907.
84. Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost. 2010;103 604-612.
85. Deinum J, Mattsson C, Inghardt T, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009;101 1051-1059.
86. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48 1-22.
87. Paccaly A, Ozoux ML, Chu V, et al. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost. 2005;94 1156-1163. (Pubitemid 41819609)
88. Paccaly A, Frick A, Rohatagi S, et al. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol. 2006;46 37-44. (Pubitemid 43021712)
89. Cohen M, Bhatt DL, Alexander JH, et al. SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention the SEPIA-PCI trial. Circulation. 2007;115 2642-2651. (Pubitemid 46791363)
90. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42) a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009;374 787-795.
91. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1 Investigators. RUBY-1 a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32 2541-2554.
92. Bowersox SS, Canafax D, Druzgala P, et al. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro- 2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. Thromb Res. 2010;126 e383-e388.
93. Choppin A, Irwin I, Lach L, et al. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. Br J Pharmacol. 2009;158 1536-1547.
94. Bavisotto LM, Ellis DJ, Milner PG, et al. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011;51 561-574.
95. Ellis DJ, Usman MH, Milner PG, et al. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120 1029-1035.
96. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007;5 746-753. (Pubitemid 46563573)
97. Kawamura M, Konishi N, Hiroe K, et al. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. J Cardiovasc Pharmacol. 2010;56 156-161.
98. Weitz JI, Cao C, Eriksson BI, et al. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010;104 1150-1157.
99. Veyrat-Follet C, Vivier N, Trellu M, et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost. 2009;7 559-565.
100. Buller HR, Cohen AT, Davidson B, et al. van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007;357 1094-1104. (Pubitemid 47443214)
101. Buller HR, Cohen AT, Davidson B, et al. van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007;357 1105-1112. (Pubitemid 47443215)
102. Savi P, Herault JP, Duchaussoy P, et al. Reversible biotinylated oligosaccharides a new approach for a better management of anticoagulant therapy. J Thromb Haemost. 2008;6 1697-1706.
103. Buller HR, Destors JM, Gallus AS, et al. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis (EQUINOX) study. J Thromb Haemost. 2011;9 92-99.
104. Büller HR, Gallus AS, Pillion G, et al. CASSIOPEA Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012;379 123-129.
105. Eikelboom JW, Weitz JI. Idrabiotaparinux treatment for venous thromboembolism. Lancet. 2012;379 96-98.
106. Rai R, Sprengeler PA, Elrod KC, et al. Perspectives on factor Xa inhibition. Curr Med Chem. 2001;8 101-119. (Pubitemid 32416446)
107. Liesenfeld KH, Schäfer HG, Trocóniz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients a population model analysis. Br J Clin Pharmacol. 2006;62 527-537. (Pubitemid 44571573)
108. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003;33 173-183. (Pubitemid 39664135)
109. Haas S. Rivaroxaban - an oral, direct Factor Xa inhibitor lessons from a broad clinical study programme. Eur J Haematol. 2009;82 339-349.
110. Perzborn E, Harwardt M. Recombinant factor VIIa partially reverses the effect of factor Xa inhibitor on thrombin generation, but not the effects of thrombin inhibitors in vitro. J Thromb Haemost. 2007;5(suppl 2) Abstract P-W-640.
111. Tinel H, Heutter J, Perzborn E. Recombinant factor VIIa partially reverses the anticoagulant effect of high-dose rivaroxaban - a novel, oral factor Xa inhibitor-in rats. J Thromb Haemost. 2007;5(suppl 2) Abstract P-W-652.
112. Perzborn E. FEIBA reverses the effects of high dose of rivaroxaban in rats. Pathophysiol Haemost Thromb. 2008;36 A40 Abstract P 061.
113. Lu G, DeGuzman F, Lakhotia S, et al. Recombinant antidote for reversal of anticoagulant by factor Xa inhibitors (abstract). Blood. 2008;112 Abstract 983.
114. Lu G, Luan P, Hollenbach S, et al. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors (abstract). J Thromb Haemost. 2009;7(suppl 2) abstract OC-TH-107.
115. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103 1116-1127.
116. Battinelli EM. Reversal of new oral anticoagulants. Circulation. 2011;124 1508-1510.
117. Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost. 2010;8 722-729.
118. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47 203-216.
119. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115 15-20.
120. Fox M, Dunham W, Walsh E. Cash-strapped US patients may be skipping drugs. Available at http //www.reuters.com/article/healthNews/ idUSTRE5196SR20090211. Accessed April 29, 2011.
121. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154 1-11.
122. Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150 73-83.
123. Leey JA, McCabe S, Koch JA, et al. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am J Geriatr Pharmacother. 2009;7 197-203.
124. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010;55 2804-2812.
125. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy a systematic review and economic modelling. Health Technol Assess. 2007;11 iii-iv, ix.
126. Heneghan C, Ward A, Perera R, et al. Self-Monitoring Trialist Collaboration. Self-monitoring of oral anticoagulation systematic review and meta-analysis of individual patient data. Lancet. 2012;379 322-334.
127. Kyrle PA, Eichinger S. Vitamin K antagonists self-determination by self-monitoring? Lancet. 2012;379 292-293.